Abstract: The invention involves the pharmaceutical use of honokiol, in particular the use of honokiol in inhibiting medulloblastoma, and it has been experimentally proved that honokiol can inhibit the proliferation and induce cell cycle arrest and apoptosis of medulloblastoma cells; promoting hair growth, and it has been experimentally proved that honokiol can promote hair growth and has no toxic and side effects on liver and kidney; and promoting white hair blackening, and it has been experimentally proved that honokiol can promote white hair blackening and has no toxic side effects on liver and kidney.
Type:
Application
Filed:
December 10, 2020
Publication date:
March 31, 2022
Applicants:
Chengdu Jinrui Foundation Biotech Co., Ltd., Beijing Tiantan Hospital, Capital Medical University
Inventors:
Wenbin Li, Shenglan Li, Neng Qiu, Haoyu Ye
Abstract: Disclosed in the present invention are an edaravone pharmaceutical composition and an application thereof as a sublingual preparation, the pharmaceutical composition containing edaravone or a salt thereof and mannitol. A sublingual administration preparation can avoid the first-pass effect of the liver, and samples feature good stability, convenience of transport and of use, among other advantages.
Type:
Application
Filed:
December 27, 2018
Publication date:
August 12, 2021
Applicants:
BEIJING TIANTAN HOSPITAL, CAPITAL MEDICAL UNIVERSITY, NANJING BAIXINYU PHARMACEUTICAL CO. LTD.